Anjay Rastogi
Overview
Explore the profile of Anjay Rastogi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henner D, Drambarean B, Gerbeling T, Kendrick J, Kendrick W, Koester-Wiedemann L, et al.
PLoS One
. 2025 Jan;
20(1):e0266281.
PMID: 39888902
Background: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD). Many recommendations in the Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder guidelines are supported...
2.
Dasgupta I, Meadowcroft A, Bhatt P, Acharya A, Aarup M, Correa-Rotter R, et al.
Nephrol Dial Transplant
. 2025 Jan;
PMID: 39817409
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup...
3.
Pollack Jr C, Arroyo D, Kanda E, Lazaro I, Lesen E, Franzen S, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39659133
Aims: Renin-angiotensin-aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi...
4.
Rastogi A, Chertow G, Collins A, Kelepouris E, Kotzker W, Middleton J, et al.
Adv Kidney Dis Health
. 2024 Nov;
31(6):514-522.
PMID: 39577885
Two potassium (K) binders-patiromer sorbitex calcium and sodium zirconium cyclosilicate-are recommended by international guidelines for the management of hyperkalemia. There is, however, no universally accepted best practice for how to...
5.
Tangri N, Rastogi A, Sofue T
Adv Ther
. 2024 Sep;
41(11):3973-3976.
PMID: 39298075
This is a summary of the original article 'Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan'....
6.
Rastogi A, Collins A, Kelepouris E, Kotzker W, Middleton J, Rajpal M, et al.
J Prim Care Community Health
. 2024 Aug;
15:21501319241259905.
PMID: 39143759
Introduction: There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to...
7.
Rastogi A, Pollack Jr C, Lazaro I, Lesen E, Arnold M, Franzen S, et al.
Clin Kidney J
. 2024 May;
17(5):sfae083.
PMID: 38699484
Background: This observational cohort study compared the likelihood of maintained (stabilized/up-titrated) renin-angiotensin-aldosterone system inhibitor (RAASi) therapy at 6 months following hyperkalaemia in patients with chronic kidney disease (CKD) and/or heart...
8.
Fishbane S, Clegg D, Lerma E, Rastogi A, Budden J, Morin I, et al.
Am J Nephrol
. 2024 Jan;
55(3):329-333.
PMID: 38253036
Introduction: Black and African American (AA) people are over-represented in the kidney failure population; therefore, the safety and efficacy of difelikefalin in Black/AA patients was evaluated. Methods: This was a...
9.
Tangri N, Rastogi A, Nekeman-Nan C, Hong L, Ozaki A, Franzen S, et al.
Adv Ther
. 2024 Jan;
41(3):1151-1167.
PMID: 38240949
Introduction: Sodium-glucose cotransporter 2 inhibitors such as dapagliflozin have been proven effective for slowing chronic kidney disease (CKD) progression in large outcomes trials that mainly included patients with higher levels...
10.
Drawz P, Lenoir K, Rai N, Rastogi A, Chu C, Rahbari-Oskoui F, et al.
Clin J Am Soc Nephrol
. 2023 Oct;
19(2):213-223.
PMID: 37883184
Background: Intensive BP lowering in the Systolic Blood Pressure Intervention Trial (SPRINT) produced acute decreases in kidney function and higher risk for AKI. We evaluated the effect of intensive BP...